Phase II Trial Of Eltrombopag For Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia
Jain N, Keating MJ, Burger JA, et al.
Key Points:
Phase II trial of eltrombopag in pts with CLL/SLL
10/22 patients had CLL-associated ITP and 12/22 pts had thrombocytopenia secondary to CLL marrow involvement
Overall response rate: 55%(10 CR, 2 MR), 80% (7 CR, 1 MR)in CLL-associated ITP group and 33% (3 CR, 1 MR) in the thrombocytopenia secondary to CLL marrow involvement
Responding patients treated with eltrombopag for a median of 5.8 months (range, 2.8-21)
Implications:
- Eltrombopag effective in treating ITP-associated thrombocytopenia in patients with CLL patients.
View the original abstract on the ASH website.
